A real world study of levamlodipine benzenesulfonic acid tablets (Shihuida) for the clinical treatment of patients with chronic kidney disease (CKD) with hypertension based on

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000037643

Enrollment

Unknown

Registered

2020-08-29

Start date

2020-09-14

Completion date

Unknown

Last updated

2020-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension

Interventions

Case series:Take Shihuida for hypertension

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years; 2. Systolic blood pressure >= 140mmHg and/or diastolic blood pressure >= 90mmHg, or receiving antihypertensive drug treatment; 3. Meet the diagnostic criteria for chronic kidney disease (CKD) and kidney transplant patients; 4. Be willing to sign informed consent and accept accompanying visitors.

Exclusion criteria

Exclusion criteria: Levamlodipine of p-benzenesulfonic acid tablets (Shihuida) have contraindications.

Design outcomes

Primary

Measure	Time frame
Blood pressure compliance rate;After taking Shihuida, renal function changes, trace albumin, creatinine, urea;Cardiovascular and cerebrovascular complex endpoint event;Adverse events;	—

Countries

China

Contacts

Public ContactJianghua Chen

the First Affiliated Hospital, College of Medicine, Zhejiang University

zyyyrct2010@163.com+86 13905814085

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026